The DOI matches its Crossref record.
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis
Open accessAbstract
Background & aims Long-term ursodeoxycholic acid (UDCA) therapy slows the progression of primary biliary cirrhosis. This study examined the effect of UDCA therapy on survival free of liver transplantation in a large group of patients.Methods Data from three clinical trials were combined in which patients with primary biliary cirrhosis were randomly assigned to receive UDCA (n = 273) or placebo (n = 275). After 2 years, patients from French and Canadian studies received UDCA for up to 2 years. Patients from the American study remained on their assigned treatment for up to 4 years.Results Survival free of liver transplantation was significantly improved in the patients treated with UDCA compared with the patients originally assigned to placebo (P < 0.001; relative risk, 1.9; 95% confidence interval, 1.3-2.8). Subgroup analyses showed that survival free of liver transplantation was significantly improved in medium- and high-risk groups (serum bilirubin level, 1.4 to 3.5 or > 3.5 mg/dL; P < 0.0001 and P < 0.03, respectively) and histological stage IV subgroup (P < 0.01).Conclusions Long-term UDCA therapy improves survival free of liver transplantation in patients with moderate or severe disease. An effect in patients with mild disease is probably not found because they do not progress to end-stage disease in 4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies with extended follow-up have also shown improved survival.(59,62,63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, patients with earlier histologic stage usually respond more favorably to UDCA than patients with advanced disease, although patients with advanced disease may benefit in survival or avoid liver transplantation with this therapy.(63)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with ursodeoxycholic acid decreases the levels of the biochemical markers of cholestasis and extends the time to liver transplantation.4,5”
From A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Research works printed but not linked: 7
- [2]2. Babbs C, Hunt LP, Haoubi NY, Smith A, Rowan BP, Warnes TW. sponse to ursodeoxycholic acid. Gut 1995;36:935-938. Type III procollagen peptide: a marker of disease activity and 15. Christensen E, Crowe JP, Doniach D, Popper H, Ranek L, Rode ´s prognosis in primary biliary cirrhosis. Lancet 1988;1:1021- J, Tygstrup N, Williams R. Clinical pattern and course of disease 1024. in primary biliary cirrhosis based on an analysis of 236 patients.
- [3]3. Poupon RE, Balkau B, Gue ´chot J, Heintzmann F. Predictive fac- Gastroenterology 1980;78:236-246. tors in ursodeoxycholic acid-treated patients: role of serum mark- 16.
- [4]4. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival ers of connective tissue. Hepatology 1994;19:635-640. of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:701-713.
- [5]5. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic Received June 20, 1996. Accepted March 14, 1997. factor in primary biliary cirrhosis. Gut 1979;20:137-140. Address requests for reprints to: Rene ´e E. Poupon, Dr. Sci., IN- 18.
- [6]6. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance SERM Unite ´21, 16, Avenue Paul-Vaillant-Couturier, 94807 Villejuif of clinical and histological features in asymptomatic and symp- Cedex, France. Fax: (33) 01-4726-9454. tomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7. The authors thank Anne-Marie Bonnand for her helpful discussion
- [7]7. Christensen E, Neuberger J, Crowe JP, Altman DG, Popper H, and Christine Gue ´mene ´for her expert technical assistance. Portmann B, Doniach D, Ranek L, Tygstrup N, Williams R. Benefi- Presented, in part, at the 43rd Annual Meeting of the American cial effect of azathioprine and prediction of prognosis in primary Society for the Study of Liver Diseases, May 14-17, 1995, San biliary cirrhosis: final results of an international trial. Gastroenter- ology 1985;89:1084-1091.
- [8]8. Brunner of Brunner's Glands Johann Conrad Brunner (1653-1727) was born at Schaffhausen, Switzer- land, near the Rheinfall. He graduated from the university at Strasbourg, and later studied in Paris and then in England under Thomas Willis. He became a professor of anatomy at Heidelberg where he published his Disser- tatio inauguralis de glandulis duodeno intestino in 1687. Actually, Brunner's father-in-law J. J. Wepfer had previously described the glands of the duode- nal mucosa in 1679, but it was Brunner's inaugural dissertation that at- tracted attention, and hence the eponym. / 5E20$$0021 08-08-97 18:15:00 gasas WBS-Gastro
Cited by
Sorted by citations
Items 601–647 of 647
Caramella, C., Avouac, J., Sogni, P., Puéchal, X., Kahan, A., & Allanore, Y. (2007)
Racial disparity in primary biliary cholangitis (pbc) patients seen in an urban academic gi clinic
Naylor, P. H., Tama, M., Goyal, S., Kathi, P. R., Ehrinpreis, M. N., & Mutchnick, M. G. (2018) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2018.09.00301
Júnior, A., Menezes, L. V. P., Fahham, L., Fernandes, R. Z. S., & Teich, V. (2018) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v10.n1.p45-55
T cell responses to ursodeoxycholic acid and antibody profiles in primary biliary cholangitis
Gray, K. J. (2018) · Northumbria Research Link (Northumbria University)
Dermatoses of Pregnancy at a Glance
Roth, M.-M. (2011)
Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC
Koenen, M. T., Zimmermann, H. W., & Trautwein, C. (2019) · Gastro-News · doi:10.1007/s15036-019-0633-1
Diseases of the Liver: Primary Biliary Cholangitis
Phillips, P. K., & Said, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-25626-5_7
Yerragorla, P., Nekkalapudi, D. K., Shady, A., & Bergasa, N. V. (2020) · Archives of Clinical Gastroenterology · doi:10.17352/2455-2283.000068
Lajouad, S., Bouziane, A., Benelbaghdadi, I., Berhili, K., Lagdali, N., Borahma, M., & Ajana, F. Z. (2019) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2019.v05i11.004
Schattenberg, J. M. (2020) · Gut · doi:10.1136/gutjnl-2019-320355
Nemergut, K., & Littlewood, E. C. (2006) · Elsevier eBooks · doi:10.1016/b978-141602212-1.50008-1
Heathcote, E. J. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50048-6
Self-citationNovel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
Ahn, D. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.75.5.246
The revival of preemptive UDCA therapy in liver transplant recipients
Corpechot, C. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101679
Vergani, L., Baldini, F., Khalil, M., Serale, N., Baj, J., Ciaula, A. D., & Portincasa, P. (2021) · The International Journal of Gastroenterology and Hepatology Diseases · doi:10.2174/2666290601666210421132727
NSAID-induced liver damage with cholestasis
Pereverzev, A. P., Ostroumova, O. D., Головина, О. В., Филиппова, А. В., & Павлеева, Е. Е. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-23-37-48
Treatment of primary biliary cirrhosis: current standards
Poupon, R. Y., Corpechot, C., Carrat, F., Chrétien, Y., & Poupon, R. E. (2007) · Springer eBooks · doi:10.1007/1-4020-2916-0_17
Self-citationMarschall, H., Wagner, M., Zollner, G., Fickert, P., Gumhold, J., Silbert, D., Diczfalusy, U., Benthin, L., Grundström, R., Gustafsson, U. O., et al. (2007) · Springer eBooks · doi:10.1007/1-4020-2913-6_28
Dancygier, H. (2003) · Springer eBooks · doi:10.1007/978-3-642-55902-0_25
Trauner, M. A., & Boyer, J. L. (2000) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200005000-00006
Glantz, A., Reilly, S., Benthin, L., Lammert, F., Mattsson, L.-Å., Sjövall, J., & Marschall, H. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6252-0_21
Pathomechanisms of cholestasis: targets for medical treatment
Paumgartner, G. (2007) · Springer eBooks · doi:10.1007/1-4020-2916-0_15
Poupon, R. Y. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6252-0_22
Self-citationAngulo, P., & Dickson, E. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70319-7
Self-citationUrsodiol and combination therapy
Carithers, R. L. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_18
Steinmann, S., & Schramm, C. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01674-7
ATMANI, I., Lahlali, M., Lamine, A., Lahmidani, N., ElMekkaoui, A., Yousfi, M. E., Benajah, D., Abkari, M. E., Ibrahimi, A., & Abid, H. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.22.2.1435
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Ursodeoxycholic acid in hepatobiliary diseases
Kim, H., & Yoo, J. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.9.603
Verschlussikterus, Gallengangsstrikutren, Autoimmuncholangitis, Gallengangsfisteln
Hartmann, D., & Jakobs, R. (2024) · Springer Reference Medizin · doi:10.1007/978-3-662-61724-3_128-1
Iqirvo for primary biliary cholangitis – efficacy, safety, and future directions
Saleem, R., Shakeel, A., Riaz, R., Noman, F., & Nasser, N. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003183 · Cited by 1
PPAR-Agonisten - etablierte Substanzen und neue Entwicklungen
Herta, T., & Tacke, F. (2025) · Gastro-News · doi:10.1007/s15036-025-3896-8
Qasim, B., Kumari, H., Kashif, S. N., Abbas, S. M. I., Hani, O., Salma, O., Sauleh, A., Adnan, F., Ali, M., Raheem, A., et al. (2025) · Egyptian Liver Journal · doi:10.1186/s43066-025-00464-6
Medikamentöse Therapie der Komplikationen der Leberzirrhose
Grünhage, F., Heller, J., Appenrodt, B., Schmitz, V., & Sauerbruch, T. (2008) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-008-1072-5
Gotaro, T. O. D. A., 大海, 石., 三朗, 大., Okanoue, T., 森一, 恩., Kako, M., Kaneko, S., 朝輝, 上., 寛中, 川., Sata, M., et al. (2011) · Kanzo · doi:10.2957/kanzo.52.584
Liver transplant and autoimmune liver diseases: An up-to-date review
Freire, J. P. C., Lopes, C. F., Lima, P. H. M., Feliciano, L. D., & de Melo, F. F. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i3.114915
The Liver in Pediatric Rheumatology: A Comprehensive Review
Jariwala, M. P., Kerr, T., & Kehar, M. (2026) · Livers · doi:10.3390/livers6030037
American Association for the Study of Liver Diseases, & EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER (2026) · Hepatology · doi:10.1097/hep.0000000000001791
AISF practice guidance on the treatment of primary biliary cholangitis: A 2026 update
Aghemo, A., Calvaruso, V., Carbone, M., Cazzagon, N., Cristoferi, L., D’Amato, D., D’Ambrosio, R., Fianchi, F., Germani, G., Giannini, E. G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.019
Austrian Society of Gastroenterology and Hepatology (ÖGGH) consensus on primary biliary cholangitis
Halilbasic, E., Tatscher, E., Aigner, E., Burghart, L., Graziadei, I. W., Hametner‐Schreil, S., Hofer, B., Hofer, H., Maieron, A., Mandorfer, M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02798-6
Khurram, N. A., Stanton, K., Miller, A., Varshney, N., Barwad, A., Sharma, C. B., Baroudi, I., Davis, K., McGrath, N. G., & Zhang, P. J. L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156690
Diagnosis and UDCA Treatment of Primary Biliary Cirrhosis
Tanaka, A. (2014) · Springer eBooks · doi:10.1007/978-4-431-54789-1_18
Old and new immunosuppressant drugs: mechanisms and potential value
Vierling, J. M. (1998) · Springer eBooks · doi:10.1007/978-94-011-4884-9_14
Metadata
- Authors
- Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E.
- Affiliations
- Mayo Clinic (US)
- Inserm (FR)
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1997-09
- Volume
- 113
- Issue
- 3
- Pages
- 884-890
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2071394537
- Semantic Scholar
- b05e12d331fd48ec432f894f09036aaff9a53c62
- Cited by
- 648
- References
- 0
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 21 · 2019: 23 · 2018: 27 · 2017: 26 · 2016: 12 · 2015: 24 · 2014: 26 · 2013: 13 · 2012: 17
- FWCI
- 21.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- ursodeoxycholic acid, primary biliary cirrhosis, liver transplantation, disease severity, serum bilirubin, subgroup analysis, treatment efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Cause of Death, Female, Forecasting, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Postoperative Care, Severity of Illness Index, Ursodeoxycholic Acid, Survival Analysis, Liver Transplantation, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
